B
BioRender
Science visualization platform for the pharmaceutical and life sciences industries
About BioRender
BioRender is a pioneering startup that has transformed the way scientists create and share scientific illustrations. Operating in the life sciences market, BioRender offers an online platform with thousands of pre-drawn icons and templates from over 30 fields of life sciences. This software is specifically designed to help scientists, researchers, and educators produce professional, accurate, and visually appealing scientific figures quickly and efficiently.
The company serves a diverse range of clients, including academic researchers, pharmaceutical companies, biotech firms, and educational institutions. These clients use BioRender to create figures for research papers, presentations, grant applications, and educational materials. By providing a user-friendly interface and a vast library of customizable icons and templates, BioRender significantly reduces the time and effort required to produce high-quality scientific illustrations.
BioRender operates on a subscription-based business model. Users can choose from various subscription plans that offer different levels of access to the platform's features and resources. The company generates revenue through these subscription fees, which can be billed monthly or annually. Additionally, BioRender may offer enterprise solutions for larger organizations that require more extensive use of the platform.
In summary, BioRender is a game-changer in the scientific community, enabling users to create professional scientific figures with ease. Its innovative approach and comprehensive resources make it an invaluable tool for anyone involved in scientific research and communication.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Toronto, Canada
- Employees
- 253
- Open positions
- 38
- Dealroom signal
- 86.9/100
- Industry
- Health, Marketing
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Cloud Data Services, Graphic Design, Biotechnology, Biotech and Pharma, Hard Tech, YC W18, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Dec 2025 | $0 | $900M | Dimension | ↗ |
| SERIES AEquity / VC | Apr 2023 | $17M | $68M | Sequoia · Y Combinator | — |
Growth signals
Latest recorded traffic for BioRender is 2M monthly website visits, down 13% over the last three months. BioRender's team grew 15% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Ontario Centre of Innovation
Y Combinator
Brad Flora
Series A2 investors entered at this stage
Sequoia
Dimension
Other known investors4 additional known investors
Fifty Years
FundersClub
Refactor Capital
Zeno Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioRender on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioRender’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.